磯部 大地

Medicine & Life Sciences

1. Neoplastic Stem Cells 100%
2. amrubicin 67%
3. Drug Therapy 64%
4. Colorectal Neoplasms 48%
5. human STEAP1 protein 44%
6. Nivolumab 41%
7. Organoids 41%
8. Stomach Neoplasms 41%
9. Irinotecan 35%
10. Neoplasms 33%
11. eribulin 32%
12. Adenocarcinoma 30%
13. Self Expandable Metallic Stents 28%
14. Neuroendocrine Carcinoma 25%
15. Atlases 24%
16. Small Cell Carcinoma 23%
17. Survival 23%
18. Gastrointestinal Neoplasms 23%
19. Oxaliplatin 23%
20. B-Lymphocytes 22%
21. RNA Sequence Analysis 21%
22. gemcitabine 21%
23. Bevacizumab 21%
24. Squamous Cell Carcinoma of Head and Neck 21%
25. Platinum 20%
26. Gallbladder 20%
27. Cadherins 19%
28. Combination Drug Therapy 19%
29. Stomach 19%
30. Contraindications 19%
31. DNA Methylation 19%
32. Quality of Life 18%
33. Sarcoma 18%
34. Doxorubicin 18%
35. Drug Resistance 17%
36. Cell Line 17%
37. Methylation 17%
38. C-Reactive Protein 17%
39. Genes 16%
40. Albumins 16%
41. Growth 16%
42. Prostate 16%
43. Japan 16%
44. Appointments and Schedules 15%
45. Stem Cells 15%
46. Gene Expression 15%
47. Pathologic Constriction 15%
48. Pyloric Antrum 15%
49. Cellular Senescence 14%
50. Epithelial Cell Adhesion Molecule 14%